Lexicon Pharmaceuticals Inc.

06/30/2022 | Press release | Distributed by Public on 06/30/2022 10:53

LEXICON ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY OF LX9211 IN PAINFUL DIABETIC NEUROPATHY - Form 8-K